Navigation Links
Janssen Biotech, Inc. Announces Collaborative Development and Worldwide License Agreement for Investigational Anti-Cancer Drug, PCI-32765
Date:12/8/2011

HORSHAM, Pa., Dec. 8, 2011 /PRNewswire-FirstCall/ -- Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson (NYSE: JNJ), announced today that it has executed an agreement with Pharmacyclics, Inc. (Nasdaq: PCYC) to jointly develop and market the anti-cancer compound, PCI-32765.  A number of Phase 1 and 2 studies with PCI-32765 are ongoing across a panel of B-cell malignancy disorders, including chronic lymphocytic leukemia, mantle cell lymphoma, and diffuse large B-cell lymphoma.  Interim data were reported at the 2011 American Society of Clinical Oncology Annual Meeting and oral presentations on two separate Phase 2 studies will be presented at the upcoming American Society of Hematology Meeting in December, along with several other poster presentations.

"The agreement with Pharmacyclics is an opportunity to bring a new form of oral therapy to patients with B-cell malignancies," said William N. Hait, M.D., Ph.D., Global Therapeutic Head, Oncology, for Janssen.  "PCI-32765 is an innovative compound, with broad applicability and the potential to help a large number of patients with B-cell malignancies."

According to the terms of the agreement, the companies have entered into a worldwide 50/50 profit-loss agreement, sharing development and commercialization activities.  Janssen has made an upfront payment of $150 million which will be recorded in the fourth quarter, and will make additional payments based upon the achievement of certain development and regulatory milestones.  This transaction is expected to have a dilutive impact to Johnson & Johnson's 2011 earnings per share of approximately $0.04 - $0.05.

About PCI-32765

PCI-32765 is an orally active, small molecule inhibitor of Bruton's tyrosine k
'/>"/>

SOURCE Janssen Pharmaceutical Companies of Johnson & Johnson
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Johnson & Johnson Symposium Honors 2011 Recipient of The Dr. Paul Janssen Award for Biomedical Research
2. FDA Issues Complete Response Letter to Janssen Biotech, Inc. for SIMPONI® Supplemental Biologic License Application
3. Skyline Diagnostics Establishes Research Collaboration With Janssen
4. Johnson & Johnson Honors 2009 Recipient of The Dr. Paul Janssen Award for Biomedical Research
5. Video: Axel Ullrich Named Winner of 2009 Dr. Paul Janssen Award for Biomedical Research
6. Johnson & Johnson Honors 2008 Recipients of The Dr. Paul Janssen Award for Biomedical Research
7. Kibow Biotech, Inc. Secures $2.4 Million Towards Its Human Clinical Trials by Continued Veterinary Licensing Agreement
8. C3i Inc to Provide Full-Service Technology Support and Oracle Clinical, Oracle Remote Data Capture Business Process Outsourcing to XBiotech, Inc
9. Genesis Biopharma to Present at the Informed Investors Forum Biotech, Healthcare & Pharma Virtual Conference on October 13
10. For the First Time, a Glioma - Brain Cancer - may be Eliminated by a Chinese Research/Medical Team, Using a Novel Stem Cell Based Therapy of Cellonis Biotech, Beijing
11. For the First Time, a Glioma ¨C Brain Cancer ¨C may be Eliminated by a Chinese Research/Medical Team, Using a Novel Stem Cell Based Therapy of Cellonis Biotech, Beijing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)... , Mar. 04, 2015 Research and ... the addition of the "Global Biologics and ... offering. , The Global Biologics ... and in-depth study on the current state of ... report provides a basic overview of the industry ...
(Date:3/4/2015)... Proove Biosciences , a ... excited to announce the launch of their CME-accredited ... Management of Pain”. , The continuing medical education ... next year. The focus of the program is ... pain treatments, integrate appropriate pain management techniques, and ...
(Date:3/4/2015)... Vegalab announced the acquisition of Ecowin, a ... As part of the acquisition, Ecowin rebranded itself as ... role as CEO for the company,s Korea operations. ... alongside Koo and oversee developments at the new location. ... Koo founded Ecowin in 2008 to great ...
(Date:3/4/2015)... PARIS , March 4, 2015 ... Hopitaux de Paris en ... «   SARAH   », qui compare   ... l,yttrium-90 avec le   sorafénib dans le carcinome ... atteints d,un cancer du foie avancé   ; ...
Breaking Biology Technology:Global Biologics and Biosimilars Industry Report 2015-2020 2Proove Biosciences Launches CME Accredited Program with Medscape 2Proove Biosciences Launches CME Accredited Program with Medscape 3Korean Government Program Supports Vegalab's Research and Development 2Korean Government Program Supports Vegalab's Research and Development 3Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 2Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 3Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 4Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 5Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 6
... , , , , Multiporator , , , , ... Transfection Protocol , Protocol No. 4308 915.026 11/2001 , ... , , , , , ... line), , , ...
... , , , , , Multiporator / Electroporator 2510 , , , ... Transformation Protocol , Protocol No. 4308 915.529 01/2002 , ... , , , , , ... , Cell type , ...
... , , , , , , , ... 4308 915.047 11/2001 , , , , , , ... Organism , Neurospora crassa, , ... Filamentous fungus, protoplasts, , , ...
Cached Biology Technology:Sp20-Ag14 2Sp20-Ag14 3Pseudomonas putida 2Neurospora crassa 2
(Date:3/4/2015)... , Mar. 04, 2015 Research and Markets ... addition of the "Global Biometrics Market Forecast ... The market for biometric authentication systems ... around 14% till 2020 The driving ... increasing security needs, government projects and constant development ...
(Date:3/3/2015)... FOREST, Calif. , March 3, 2015 ... the leading provider of advanced cryogenic logistics ... markets including immunotherapies, stem cells, cell lines, ... and reproductive medicine, today announced the expansion ... Cancer Research Centers, ("Fred Hutch") Clinical ...
(Date:3/2/2015)... 2, 2015 Synaptics Inc. (NASDAQ: ... interface solutions, today announced a new implementation of ... enable rapid and secure transactions and reliable identification ... is a turnkey solution providing mouse and keyboard ... integrate fingerprint ID solutions into their product offerings, ...
Breaking Biology News(10 mins):Global Biometrics Market Forecast and Opportunities, 2020 2Global Biometrics Market Forecast and Opportunities, 2020 3Cryoport, Inc. Expands Support of Fred Hutchinson Cancer Research Center's Clinical Research Division 2Cryoport, Inc. Expands Support of Fred Hutchinson Cancer Research Center's Clinical Research Division 3Synaptics Unveils New Fingerprint ID Solution for Gamers 2Synaptics Unveils New Fingerprint ID Solution for Gamers 3
... published in the Sept. 15 edition of the Journal ... Edward H. Shortliffe, MD, PhD, points out that although ... role that information management and access play in healthcare ... informatics competency being developed in America,s future corps of ...
... RICHMOND, Va. (Sept. 14, 2010) An ... gene for schizophrenia, including a potentially causative mutation, ... The results of the research, led by ... human and molecular genetics in Virginia Commonwealth University,s ...
... clinical trial to assess the use of bone marrow-derived ... infarction (STEMI; severe heart attack) demonstrated a strong safety ... results published in the September issue of the ... adult stem cells, derived from the patient,s own bone ...
Cached Biology News:Informatics = essential MD competency 2VCU study: Team uncovers possible risk gene for schizophrenia 2First US trial of bone-marrow stem cells for heart attack patients proves safe 2
... Forma Tabletop orbital shakers combine high ... use. The patented triple-counterbalanced heavy-duty mechanism prevents ... with heavy, out-of-balance loads. Every other part, ... feet, to the thick machined aluminum platform ...
...
The Holten Horizontal series of laminar airflow work benches offers comfort and ease of use....
... Fixed Angle Polypropylene Rotor designed for ... Centra CL3/CL3R** and Centra-MP4/MP4R*. A translucent ... /MP4, ,EXCLUSIVE polypropylene rotor design provides ... repeatedly autoclaved. Polypropylene rotors are ...
Biology Products: